GlassScriptPhysician profile
Shereene Idriss
NPI 1295969624
$98,464.10
in general payments reported to CMS, 2019-2025
13 companies · $72.47 in 2025
The $72.47 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $811 · 2020: $31K · 2021: $645 · 2022: $481 · 2023: $599 · 2024: $65K · 2025: $72.47.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $65K · Food and Beverage: $736.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $65,000.00 |
| Food and Beverage | $735.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $65,000.00 | 2024 | Otezla |
| Galderma Laboratories, L.P. | $30,867.52 | 2020-2025 | Dysport |
| Merz North America, INC. | $1,628.89 | 2019-2023 | |
| Allergan, INC. | $600.45 | 2019-2022 | |
| Abbvie INC. | $205.75 | 2023-2025 | |
| Biofrontera INC. | $26.43 | 2019 | |
| Sun Pharmaceutical Industries INC. | $25.17 | 2022 | |
| Dermira, INC. | $22.21 | 2019 | |
| Revance Therapeutics, INC. | $21.18 | 2024 | Daxxify |
| Dusa Pharmaceuticals, INC. | $20.29 | 2019 | |
| Aclaris Therapeutics, INC. | $18.34 | 2019 | |
| Solta Medical, A Division of Bausch Health US, LLC | $15.42 | 2023 | Clear & Brilliant |
| Leo Pharma INC. | $12.45 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shereene Idriss listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.